Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia

Informed decisions on myopia management require an understanding of financial impact. This study describes methodology for estimating lifetime myopia costs, with comparison across management options, using exemplars in Australia and China.

The study demonstrates a process for modelling lifetime costs of traditional myopia management (TMM=full, single-vision correction) and active myopia management (AMM) options with clinically meaningful treatment efficacy. Evidence-based, location-specific and ethnicity-specific progression data determined the likelihood of all possible refractive outcomes. Myopia care costs were collected from published sources and key informants. Refractive and ocular health decisions were based on standard clinical protocols that responded to the speed of progression, level of myopia, and associated risks of pathology and vision impairment.

The study concluded that financial investment in AMM during childhood may be balanced or exceeded across a lifetime by reduced refractive progression, simpler lenses, and reduced risk of pathology and vision loss. Our methodology can be applied to estimate cost in comparable scenarios.

Publication date

February 23, 2022


British Journal of Ophthalmology

Sponsor Institution

This work was supported by a public health grant from the Brien Holden Vision Institute, Sydney, Australia


Tim R. Fricke; Padmaja Sankaridurg; Thomas Naduvilath; Serge Resnikoff; Nina Tahhan; Mingguang He; Kevin D. Frick
Share this